Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial.

Abstract

BACKGROUND:

Safety of combination chemotherapy using platinum and fluorouracil has not been evaluated adequately for advanced gastric cancer (AGC) in elderly patients.

PATIENTS AND METHODS:

We initiated a phase II study to evaluate the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) as first-line therapy for patients with AGC aged ≥70 years. Planned assessment of toxicity was made upon recruitment of the first 20 patients.

RESULTS:

In five out of 20 patients, unacceptable toxicity was observed, including three patients who were unable to complete the initial two courses due to adverse events. Among the other 15 patients, dose reduction due to toxicity were needed in 10 and treatment delay for adverse events also occurred in 12 patients during the first two courses.

CONCLUSION:

Early analyses of safety suggest that the CapeOX regimen was not tolerated without dose reduction for elderly patients with AGC in this study.

• Authors: Keisho Chin, Daisuke Takahari, Ryohei Kawabata, Hisashi Hosaka, S O Saitou, Takeshi Shiraishi, Hiroshi Yabusaki, Masahiro Goto, Masato Nakamura, Hiroshi Imamura, Yoshiaki Shindo, Fumio Nagashima, Wataru Ichikawa, Takashi Saotome, Wataru Yamamoto, Naoki Ishizuka, Kensei Yamaguchi
• Journal: Anticancer research (Anticancer Res) Vol. 42 Issue 5 Pg. 2683-2687 (May 2022) ISSN: 1791-7530 [Electronic] Greece
• PMID: 35489762 (Publication Type: Clinical Trial, Phase II, Journal Article)
• Copyright: Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Oxaliplatin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Humans
• Oxaliplatin (therapeutic use)
• Stomach Neoplasms (drug therapy, pathology)